AI news ·
AI Breakthrough Enables Early Detection of Multiple Sclerosis Progression, Improving Treatment Outcomes
AI detects the shift from RRMS to SPMS in multiple sclerosis with 90% accuracy, enabling earlier treatment adjustments and improved patient outcomes. This breakthrough may slow disease progression.
Multiple Sclerosis: AI Detects Critical Transition From RRMS to SPMS
Knowing when multiple sclerosis (MS) shifts from the relapsing-remitting form (RRMS) to secondary progressive MS (SPMS) is crucial for effective treatment. Currently, this transition is identified on average three years too late, delaying adjustments in therapy that could slow disease progression.
Researchers at Uppsala University have developed an AI model capable of determining with 90% accuracy whether a patient has RRMS or has transitioned to SPMS. This advancement allows healthcare providers to start the appropriate treatment earlier, improving outcomes and potentially slowing the worsening of symptoms.
Understanding the Transition in MS
MS is a chronic inflammatory disease affecting the central nervous system. In Sweden alone, about 22,000 people live with MS. Most patients begin with RRMS, marked by periods of symptom flare-ups followed by remission. Over time, many progress to SPMS, where symptoms steadily worsen without clear periods of remission.
Distinguishing between RRMS and SPMS matters because the treatment strategies differ significantly. Delayed diagnosis of SPMS means patients may continue receiving medications effective only for RRMS, reducing treatment efficacy.
How the AI Model Works
The model analyzes clinical data from over 22,000 patients in the Swedish MS Registry. It uses information collected during routine healthcare visits, including neurological tests, MRI scans, and current treatments.
What sets this AI apart is its ability to indicate the confidence level of each assessment. This helps clinicians understand how reliable the model’s conclusion is for individual patients, adding a layer of transparency to support decision-making.
Impact on Patient Care and Research
- The AI model identified the transition to SPMS correctly or earlier than documented in nearly 87% of cases.
- Its overall accuracy reaches around 90%, allowing for timely adjustment of treatment plans.
- Earlier diagnosis reduces the risk of patients receiving ineffective medications and helps slow disease progression.
- In the future, the model could assist in selecting suitable candidates for clinical trials, advancing personalized treatment strategies.
An open, anonymized version of this AI model is now accessible to researchers through a web service, promoting further study and collaboration in MS care.
For healthcare professionals interested in AI applications in medicine, exploring courses on AI tools and data analysis can be valuable. Resources like Complete AI Training offer relevant learning opportunities.